Recce Pharmaceuticals' Anti-Infective Drug Candidate Showed Activity Against 'Superbug' in Skin Cell Study

Recce Pharmaceuticals' (ASX:RCE) skin cell study showed the efficacy of the company's drug candidate, Recce 327, as a potential anti-infective against World Health Organization priority pathogen, acin

MT NewswiresJul 7 22:41 ET

Recce Pharmaceuticals Fields Positive Efficacy Data From Murdoch Children's Research Institute Study

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has fielded some promising results from its latest study on the efficacy of RECCE® 327 (R327) against the multidrug-resistant (MDR), World Health Organization (WHO) priority pathogen Acinetobacter baumannii (A. baumannii).

Investing.com Jul 7 20:56 ET

Recce Pharmaceuticals (ASX:RCE) Firing on All Cylinders Following Completion of UTI Trial

The Market HeraldJul 3 02:58 ET

Recce Pharmaceuticals Secures Long Cash Runway for Trials After Raising $8 Million; Plans $2 Million SPP

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has raised $8 million via an institutional placement at A$0.45 per share.

Investing.com Jul 1 22:55 ET

Recce Pharmaceuticals' Phase 1/2 Urinary Tract Infection Trial Meets Primary Endpoints; Shares Up 4%

Recce Pharmaceuticals' (ASX:RCE) phase 1/2 clinical trial evaluating Recce 327 as a potential treatment for urinary tract infection or urosepsis met all primary endpoints of tolerability and "signific

MT NewswiresJun 27 20:50 ET

Recce Pharmaceuticals Secures Ethics Approval for Bacterial Skin Infection Study

Recce Pharmaceuticals (ASX:RCE) secured approval from Australia's Human Research Ethics Committee for the use of the topical medication Recce 327 in a phase two clinical trial investigating its use to

MT NewswiresJun 24 00:59 ET